Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2009.04.10, US 16841109 P
DIARRA DANIELLE ET AL: "Dickkopf-1 is a master regulator of joint remodeling", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM1538, vol. 13, no. 2, 1 February 2007 (2007-02-01), pages 156-163, XP002486201, ISSN: 1078-8956 [retrieved on 2007-01-21] (B1)
ZHOU XIAO-LEI ET AL: "Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling", ACTA PHARMACOLOGICA SINICA, vol. 31, no. 2, February 2010 (2010-02), pages 202-210, XP009134321, (B1)
FILIPPO CARACI ET AL: "The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders", NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE LNKD- DOI:10.1007/S11064-008-9710-0, vol. 33, no. 12, 22 April 2008 (2008-04-22), pages 2401-2406, XP019647587, ISSN: 1573-6903 (B1)
FULCINITI MARIATERESA ET AL: "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, UNITED STATES LNKD- DOI:10.1182/BLOOD-2008-11-191577, vol. 114, no. 2, 9 July 2009 (2009-07-09), pages 371-379, XP009134332, ISSN: 1528-0020 [retrieved on 2009-05-05] (B1)
GAVRIATOPOULOU MARIA ET AL: "Dickkopf-1: a suitable target for the management of myeloma bone disease.", EXPERT OPINION ON THERAPEUTIC TARGETS JUL 2009 LNKD- PUBMED:19530987, vol. 13, no. 7, July 2009 (2009-07), pages 839-848, XP009134320, ISSN: 1744-7631 (B1)
HALL CHRISTOPHER L ET AL: "Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis", PROSTATE, WILEY-LISS, NEW YORK, NY, US LNKD- DOI:10.1002/PROS.20805, vol. 68, no. 13, 15 September 2008 (2008-09-15), pages 1396-1404, XP009134318, ISSN: 0270-4137 [retrieved on 2008-06-16] (B1)
HEATH DEBORAH J ET AL: "Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma", JOURNAL OF BONE AND MINERAL RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW YORK, NY, US LNKD- DOI:10.1359/JBMR.081104, vol. 24, no. 3, 1 March 2009 (2009-03-01), pages 425-436, XP009134333, ISSN: 0884-0431 [retrieved on 2009-12-04] (B1)
KRAJ MARIA: "Multiple myeloma bone disease and novel anti-myeloma agents", ACTA HAEMATOLOGICA POLONICA, vol. 39, no. 2, 2008, pages 163-178, XP009134337, ISSN: 0001-5814 (B1)
MELODY MAZON ET AL: "Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?", CANCERS, vol. 8, no. 7, 28 June 2016 (2016-06-28), page 62, XP55329263, DOI: 10.3390/cancers8070062 (B1)
TERPOS E: "Antibodies to dickkopf-1 protein", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.16.10.1453, vol. 16, no. 10, 1 October 2006 (2006-10-01), pages 1453-1458, XP002486202, ISSN: 1354-3776 (B1)
WO-A1-2008/097510 (B1)
WO-A1-2010/129752 (B1)
WO-A2-2006/015373 (B1)
WO-A2-2007/084344 (B1)
YACCOBY SHMUEL ET AL: "Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2006-09-047712, vol. 109, no. 5, 1 March 2007 (2007-03-01) , pages 2106-2111, XP002486200, ISSN: 0006-4971 [retrieved on 2006-10-26] (B1)
ETTENBERG SETH A ET AL: "BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), page 947, XP009134334, ISSN: 0197-016X (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3514173)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3514173)
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 16. avg. år (EP) | 2025.03.21 | 6760 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 15. avg. år (EP) | 2024.03.22 | 6310 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 14. avg. år (EP) | 2023.03.22 | 4500 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 13. avg. år (EP) | 2022.03.24 | 4200 | 1/ANAQUA SERVICES | Betalt og godkjent |
32111287 expand_more expand_less | 2021.08.13 | 5500 | ZACCO NORWAY AS | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|